You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Details for Patent: 8,153,689

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,153,689 protect, and when does it expire?

Patent 8,153,689 protects XENLETA and is included in two NDAs.

This patent has forty-four patent family members in thirty-one countries.

Summary for Patent: 8,153,689

Title:	Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Abstract:	Disclosed are pleuromutilin derivatives of formula (I) ##STR00001## and their use in the treatment of diseases mediated by microbes.
Inventor(s):	Mang; Rosemarie (Vienna, AT), Heilmayer; Werner (Zillingtal, AT), Badegruber; Rudolf (Vienna, AT), Strickmann; Dirk B. (Vienna, AT), Novak; Rodger (Vienna, AT), Ferencic; Mathias (Vienna, AT), Bulusu; Atchyuta Rama Chandra Murty (Perchtoldsdorf, AT)
Assignee:	Nabriva Therapeutics AG (Vienna, AT)
Application Number:	13/252,732
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,153,689

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Nabriva	XENLETA	lefamulin acetate	SOLUTION;INTRAVENOUS	211673-001	Aug 19, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Nabriva	XENLETA	lefamulin acetate	TABLET;ORAL	211672-001	Aug 19, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,153,689

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	07450053	Mar 20, 2007

International Family Members for US Patent 8,153,689

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2137143	⤷ Sign Up	CA 2020 00046	Denmark	⤷ Sign Up
European Patent Office	2137143	⤷ Sign Up	PA2020531	Lithuania	⤷ Sign Up
European Patent Office	2137143	⤷ Sign Up	LUC00178	Luxembourg	⤷ Sign Up
European Patent Office	2137143	⤷ Sign Up	CR 2020 00046	Denmark	⤷ Sign Up
European Patent Office	2137143	⤷ Sign Up	301086	Netherlands	⤷ Sign Up
European Patent Office	2137143	⤷ Sign Up	132020000000167	Italy	⤷ Sign Up
European Patent Office	2137143	⤷ Sign Up	122020000080	Germany	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.